Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
The user started balding at 16/17 and tried various treatments including minoxidil, finasteride, and dutasteride with little success. They recently started applying diclofenac gel to their bald areas and noticed some hair regrowth, attributing this to diclofenac's ability to lower prolactin levels and its anti-inflammatory effects.
The user shared progress pictures after using 5% topical Minoxidil inconsistently for three months, along with starting Dutasteride two weeks ago and alternating with Finasteride. They reported no shedding and are considering switching to only Dutasteride once Finasteride runs out, while also experiencing some minor side effects that resolved quickly.
The conversation discusses finding a finasteride dosage that reduces DHT by about 25% to minimize side effects, with considerations for topical versus oral formulations. Alternatives like dutasteride mesotherapy and topical treatments are explored, with concerns about systemic absorption and potential impacts on athletic performance and hormone levels.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
The conversation is about a female seeking advice on using bicalutamide for female pattern hair loss (FPHL) and considering switching from pumpkin seed oil pills to a stronger treatment. She is looking for dosage information to discuss with her dermatologist.
The user used topical finasteride 0.3% and minoxidil 6% nightly for 6 months, then added oral finasteride 1mg daily a month ago, which improved hair density. They also started using Flakes shampoo for scalp irritation, finding it more effective than keto shampoo.
User shared 3-month progress using finasteride, 5% topical minoxidil twice daily, and weekly dermarolling. They showed before and after pictures, noting significant improvement.
The user experienced hair growth using 5% topical Minoxidil foam twice daily from October 2024 to February 2025, without using finasteride due to family history of side effects. The user is considering other treatments like topical finasteride and received positive feedback on their progress.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The user documented eight weeks of progress using 5% topical minoxidil, 1 mg oral finasteride, and weekly microneedling. They reported diffuse fill-in and new baby hairs, with plans to taper off topical minoxidil.
The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
A 30-year-old man has been treating his hair loss with 5% Minoxidil foam, a combination of 0.3% Finasteride and 6% Minoxidil at night, weekly dermastamping with 1.5 mm needles, and 1% ketoconazole shampoo 2-3 times a week for four months. He is asking for opinions on his hair regrowth and whether he can expect full recovery of his crown.
A user with diffuse thinning experienced no hair regrowth with finasteride or Avodart but slowed hair loss with Avodart. They are considering trying Minoxidil and are seeking advice on whether to use foam or liquid, and if combining it with other treatments could be beneficial, excluding micro-needling due to scalp irritation concerns.
The conversation is about a user trying a 0.2% Alfatrafiol treatment for hair loss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.
Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.
A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.
The user has been using a daily topical spray of finasteride and minoxidil, along with occasional microneedling, to address hair loss since August 2023, and is considering switching to oral medication for convenience and cost reasons. Despite progress, they are exploring options like increasing microneedling frequency or potentially undergoing a hair transplant to address a stubborn spot.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.
A 19-year-old is experiencing diffuse thinning and has been on finasteride for 6 months, noticing a slower but still concerning rate of hair loss. They started taking 0.5mg of dutasteride once a week in addition to 1.25mg of finasteride on other days and are seeking advice on this treatment approach.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.
The user has been using 0.25% topical finasteride for eight months with slight improvement and is considering switching to oral finasteride for convenience and potentially better results. Increasing the topical concentration to 0.33% or 0.5% is also an option, but oral finasteride may have more systemic side effects.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The user applied topical finasteride 0.3% and minoxidil 6% once daily, used keto shampoo weekly, and derma stamped weekly or biweekly. They noticed hair improvement, possibly due to regrowth or letting it grow longer.
The user experienced significant hair regrowth using 1mg finasteride every other day, 5% minoxidil twice daily, and ketoconazole shampoo. The progress was noted as impressive, with some users questioning the authenticity of the results.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.